• Je něco špatně v tomto záznamu ?

Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group

Members of the MS in the 21st Century Steering Group; P. Rieckmann, D. Centonze, I. Elovaara, G. Giovannoni, E. Havrdová, J. Kesselring, G. Kobelt, D. Langdon, SA. Morrow, C. Oreja-Guevara, S. Schippling, C. Thalheim, H. Thompson, P. Vermersch,...

. 2018 ; 19 (-) : 153-160. [pub] 20171121

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033465

BACKGROUND: Patient engagement is vital in multiple sclerosis (MS) in order to optimise outcomes for patients, society and healthcare systems. It is essential to involve all stakeholders in potential solutions, working in a multidisciplinary way to ensure that people with MS (PwMS) are included in shared decision-making and disease management. To start this process, a collaborative, open environment between PwMS and healthcare professionals (HCPs) is required so that similarities and disparities in the perception of key areas in patient care and unmet needs can be identified. With this patient-centred approach in mind, in 2016 the MS in the 21st Century Steering Group formed a unique collaboration to include PwMS in the Steering Group to provide a platform for the patient voice. METHODS: The MS in the 21st Century initiative set out to foster engagement through a series of open-forum joint workshops. The aims of these workshops were: to identify similarities and disparities in the perception and prioritisation in three key areas (unmet needs, the treatment burden in MS, and factors that impact patient engagement), and to provide practical advice on how the gaps in perception and understanding in these key areas could be bridged. RESULTS: Combined practical advice and direction are provided here as eight actions: 1. Improve communication to raise the quality of HCP-patient interaction and optimise the limited time available for consultations. 2. Heighten the awareness of 'hidden' disease symptoms and how these can be managed. 3. Improve the dialogue surrounding the benefit versus risk issues of therapies to help patients become fully informed and active participants in their healthcare decisions. 4. Provide accurate, lucid information in an easily accessible format from reliable sources. 5. Encourage HCPs and multidisciplinary teams to acquire and share new knowledge and information among their teams and with PwMS. 6. Foster greater understanding and awareness of challenges faced by PwMS and HCPs in treating MS. 7. Collaborate to develop local education, communication and patient-engagement initiatives. 8. Motivate PwMS to become advocates for self-management in MS care. CONCLUSION: Our study of PwMS and HCPs in the MS in the 21st Century initiative has highlighted eight practical actions. These actions identify how differences and gaps in unmet needs, treatment burden, and patient engagement between PwMS and HCPs can be bridged to improve MS disease management. Of particular interest now are patient-centred educational resources that can be used during time-limited consultations to enhance understanding of disease and improve communication. Actively bridging these gaps in a joint approach enables PwMS to take part in shared decision-making; with improved communication and reliable information, patients can make informed decisions with their HCPs, as part of their own personalised disease management.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033465
003      
CZ-PrNML
005      
20210510111211.0
007      
ta
008      
181008s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.msard.2017.11.013 $2 doi
035    __
$a (PubMed)29241142
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Rieckmann, Peter $u Medical Park Loipl, Bischofswiesen, Germany. Electronic address: msin21stcentury@ch-iscience.co.uk.
245    10
$a Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group / $c Members of the MS in the 21st Century Steering Group; P. Rieckmann, D. Centonze, I. Elovaara, G. Giovannoni, E. Havrdová, J. Kesselring, G. Kobelt, D. Langdon, SA. Morrow, C. Oreja-Guevara, S. Schippling, C. Thalheim, H. Thompson, P. Vermersch, K. Aston, B. Bauer, C. Demory, MP. Giambastiani, J. Hlavacova, J. Nouvet-Gire, G. Pepper, M. Pontaga, E. Rogan, C. Rogalski, P. van Galen, AF. Ben-Amor,
520    9_
$a BACKGROUND: Patient engagement is vital in multiple sclerosis (MS) in order to optimise outcomes for patients, society and healthcare systems. It is essential to involve all stakeholders in potential solutions, working in a multidisciplinary way to ensure that people with MS (PwMS) are included in shared decision-making and disease management. To start this process, a collaborative, open environment between PwMS and healthcare professionals (HCPs) is required so that similarities and disparities in the perception of key areas in patient care and unmet needs can be identified. With this patient-centred approach in mind, in 2016 the MS in the 21st Century Steering Group formed a unique collaboration to include PwMS in the Steering Group to provide a platform for the patient voice. METHODS: The MS in the 21st Century initiative set out to foster engagement through a series of open-forum joint workshops. The aims of these workshops were: to identify similarities and disparities in the perception and prioritisation in three key areas (unmet needs, the treatment burden in MS, and factors that impact patient engagement), and to provide practical advice on how the gaps in perception and understanding in these key areas could be bridged. RESULTS: Combined practical advice and direction are provided here as eight actions: 1. Improve communication to raise the quality of HCP-patient interaction and optimise the limited time available for consultations. 2. Heighten the awareness of 'hidden' disease symptoms and how these can be managed. 3. Improve the dialogue surrounding the benefit versus risk issues of therapies to help patients become fully informed and active participants in their healthcare decisions. 4. Provide accurate, lucid information in an easily accessible format from reliable sources. 5. Encourage HCPs and multidisciplinary teams to acquire and share new knowledge and information among their teams and with PwMS. 6. Foster greater understanding and awareness of challenges faced by PwMS and HCPs in treating MS. 7. Collaborate to develop local education, communication and patient-engagement initiatives. 8. Motivate PwMS to become advocates for self-management in MS care. CONCLUSION: Our study of PwMS and HCPs in the MS in the 21st Century initiative has highlighted eight practical actions. These actions identify how differences and gaps in unmet needs, treatment burden, and patient engagement between PwMS and HCPs can be bridged to improve MS disease management. Of particular interest now are patient-centred educational resources that can be used during time-limited consultations to enhance understanding of disease and improve communication. Actively bridging these gaps in a joint approach enables PwMS to take part in shared decision-making; with improved communication and reliable information, patients can make informed decisions with their HCPs, as part of their own personalised disease management.
650    _2
$a dospělí $7 D000328
650    12
$a osobní újma zaviněná nemocí $7 D017281
650    12
$a rozhodování $7 D003657
650    12
$a management nemoci $7 D019468
650    12
$a výchova a vzdělávání $7 D004493
650    _2
$a lidé $7 D006801
650    _2
$a roztroušená skleróza $x terapie $7 D009103
650    12
$a odhad potřeb $7 D020380
650    12
$a vzdělávání pacientů jako téma $7 D010353
650    12
$a zapojení pacienta $7 D010358
650    12
$a vztahy mezi zdravotnickým pracovníkem a pacientem $7 D011369
655    _2
$a časopisecké články $7 D016428
700    1_
$a Centonze, Diego $u Università di Roma Tor Vergata, Rome & IRCCS Neuromed, Pozzilli, IS, Italy.
700    1_
$a Elovaara, Irina $u Tampere University Hospital, Tampere, Finland.
700    1_
$a Giovannoni, Gavin $u Blizard Institute, Bart's School of Medicine and Dentistry, London, UK. $7 xx0260369
700    1_
$a Kubala Havrdová, Eva, $u Dept of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic. $d 1955- $7 nlk19990073204
700    1_
$a Kesselring, Jurg $u Kliniken Valens, Valens, Switzerland.
700    1_
$a Kobelt, Gisela $u European Health Economics, Spéracèdes, France. $7 xx0132640
700    1_
$a Langdon, Dawn $u Royal Holloway, University of London, Egham, UK.
700    1_
$a Morrow, Sarah A $u Western University, London, Ontario, Canada.
700    1_
$a Oreja-Guevara, Celia $u University Hospital San Carlos, Madrid, Spain.
700    1_
$a Schippling, Sven $u Universitätsspital Zürich, Zurich, Switzerland.
700    1_
$a Thalheim, Christoph $u European Multiple Sclerosis Platform, Brussels, Belgium. $7 xx0260375
700    1_
$a Thompson, Heidi $u Northern Ireland Neurology Service, Portadown, UK.
700    1_
$a Vermersch, Patrick $u University of Lille, Lille, France.
700    1_
$a Aston, Karen $u MS Society UK, London, UK.
700    1_
$a Bauer, Birgit $u European Multiple Sclerosis Platform, Brussels, Belgium.
700    1_
$a Demory, Christy $u National MS Society, New York, USA.
700    1_
$a Giambastiani, Maria Paz $u Asociación Discapacidad Sin Distancia, Gexto, Spain.
700    1_
$a Hlavacova, Jana $u Civic Association SMS, Prague, Czech Republic.
700    1_
$a Nouvet-Gire, Jocelyne $u Association Française des Sclérosés en Plaques, Blagnac, France.
700    1_
$a Pepper, George $u Shift MS, Leeds, UK. $7 xx0260365
700    1_
$a Pontaga, Maija $u Latvian MS Association, Riga, Latvia.
700    1_
$a Rogan, Emma $u European Multiple Sclerosis Platform, Brussels, Belgium.
700    1_
$a Rogalski, Chrystal $u National MS Society, NC, USA.
700    1_
$a van Galen, Pieter $u European Multiple Sclerosis Platform, Brussels, Belgium.
700    1_
$a Ben-Amor, Ali-Frédéric $u Merck KGaA, Darmstadt, Germany.
773    0_
$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 19, č. - (2018), s. 153-160
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29241142 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20210510111215 $b ABA008
999    __
$a ok $b bmc $g 1339467 $s 1030459
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c - $d 153-160 $e 20171121 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace